CD19-CAR-T细胞治疗难治复发急性淋巴细胞白血病的研究进展
发布时间：2019-04-23 19:03
【摘要】：难治复发急性淋巴细胞白血病(acute lymphocytic leukemia,ALL)预后差,生存期短,其治疗已成为国际难题。嵌合抗原受体基因修饰T(chimeric antigen receptor gene-modified T,CAR-T)细胞是目前最具应用前景的靶向免疫治疗,靶向CD19的CAR-T细胞(CD19-CAR-T)治疗儿童及成人难治复发性ALL的完全缓解率(complete remission,CR)可达90%以上,疗效远高于化疗。然而,细胞因子释放综合征(cytokine release syndrome,CRS)、严重神经毒性(serious neurotoxicity,SNT)、脱靶效应以及疾病复发等严重限制了CAR-T细胞的进一步临床应用。本文主要阐述CAR-T细胞的制备技术、预处理方案、细胞输注剂量及各种并发症防治策略等最新研究进展。
[Abstract]:The treatment of refractory recurrent acute lymphoblastic leukemia (acute lymphocytic leukemia,ALL) has become an international problem because of its poor prognosis and short survival time. Chimeric antigen receptor gene modified T (chimeric antigen receptor gene-modified-T cells are the most promising target immunotherapy at present. The complete remission rate (complete remission,CR) of CAR-T cells (CD19-CAR-T) targeting CD19 in the treatment of refractory and recurrent ALL in children and adults was more than 90%, and the curative effect was much higher than that in chemotherapy. However, cytokine-releasing syndrome (cytokine release syndrome,CRS), severe neurotoxicity (serious neurotoxicity,SNT), off-target effect and relapse seriously limit the further clinical application of CAR-T cells. In this paper, the recent advances in the preparation of CAR-T cells, pretreatment schemes, dose of cell infusion and prevention and treatment strategies of various complications were reviewed.
【作者单位】： 浙江大学医学院附属第一医院骨髓移植中心;
【基金】：国家重点基础研究发展计划(973计划)基金项目(No.2015CB964900)~~
【分类号】：R733.71
，
本文编号：2463716
[Abstract]:The treatment of refractory recurrent acute lymphoblastic leukemia (acute lymphocytic leukemia,ALL) has become an international problem because of its poor prognosis and short survival time. Chimeric antigen receptor gene modified T (chimeric antigen receptor gene-modified-T cells are the most promising target immunotherapy at present. The complete remission rate (complete remission,CR) of CAR-T cells (CD19-CAR-T) targeting CD19 in the treatment of refractory and recurrent ALL in children and adults was more than 90%, and the curative effect was much higher than that in chemotherapy. However, cytokine-releasing syndrome (cytokine release syndrome,CRS), severe neurotoxicity (serious neurotoxicity,SNT), off-target effect and relapse seriously limit the further clinical application of CAR-T cells. In this paper, the recent advances in the preparation of CAR-T cells, pretreatment schemes, dose of cell infusion and prevention and treatment strategies of various complications were reviewed.
【作者单位】： 浙江大学医学院附属第一医院骨髓移植中心;
【基金】：国家重点基础研究发展计划(973计划)基金项目(No.2015CB964900)~~
【分类号】：R733.71
，
本文编号：2463716
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2463716.html
